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Summary A double-institution phase II study was performed in patients with metastatic renal cell carcinoma
treated subcutaneously (s.c.) with interleukin 2 (IL-2) and alpha-interferon (INF-x). Thirty-eight patients were
treated over a course of 7 weeks. Initially (day 1 + 2) patients received s.c. IL-2 at 18 x 106 IU m-2. During the
following 6 weeks, patients received s.c. IL-2 at 3.6 x 106 IUm-2 for 5 days per week and s.c. INF-a at
5 x 106 for 3 days per week. Thirty-eight patients were evaluated for response. An objective response was seen
in seven patients (18.4 ± 12.3%), with one complete response and six partial responses. Median duration of
response was 6.7 months. Toxicity could be evaluated in 38 patients and was limited. Mild to moderate
toxicity included fever (97%), fatigue or malaise (76%), nausea or vomiting (50%), anorexia (32%), hypoten-
sion (26%), neurological disturbances (26%) and hypercreatininaemia (39%). In addition, four grade IV
haematological toxicities were noted. No cardiac side-effects were seen. IL-2 and INF-a given by this schedule
can be safely administered in an outpatient setting. The objective response rate was similar to our previous
treatments with high-dose IL-2 given as a continuous infusion.
In patients with metastatic renal cell carcinoma, recombinant
interleukin 2 (IL-2) administered either alone or in combina-
tion with lymphokine-activated killer (LAK) cells has given
objective response rates of 16-35% (Rosenberg et al., 1987,
1989a; West et al., 1987; Fisher et al., 1988; Negrier et al.,
1989; Dillman et al., 1991; Von der Maase et al., 1991). In
most clinical studies, IL-2 was given either as an intravenous
bolus (i.v.) every 8 h (Rosenberg et al., 1987, 1989a; Fisher et
al., 1988) or as a 5 day continuous infusion (West et al.,
1987; Negrier et al., 1989; Dillman et al., 1991; Von der
Maase et al., 1991). Because severe side-effects are frequent
with these protocols (Lotze et al., 1986; Margolin et al., 1989;
Ravaud et al., 1991; Siegel & Puri, 1991), a thorough patient
selection has to be done and treatment has to be admini-
stered in an intensive care unit or in a monitored standard
oncology ward.
Alpha-interferon (INF-ac) has also shown some therapeutic
efficacy in patients with metastatic renal cell carcinoma, re-
sulting in a 15% response rate (Quesada et al., 1985).
In experimental murine models, the anti-tumour effect of a
combination of IL-2 and INF-a proved to be greater than
was achieved with either agent alone (Cameron et al., 1988).
However, when patients with metastatic renal cell carcinoma
were treated with the same combination of cytokines, the
objective response rate obtained was 11-38% (Rosenberg et
al., 1989b; Atkins et al., 1991); thus the addition of INF-a to
the treatment of renal cell carcinoma with IL-2 did not
appear to increase the response. It was argued that response
rate might be related to the dose of cytokines given
(Rosenberg et al., 1989b), although increasing cytokine doses
resulted in higher toxicity (Rosenberg et al., 1989b; Atkins et
al., 1991).
Based on the substantiated synergy of these two cytokines,
we have conducted a phase II trial of IL-2 and INF-a in
metastatic renal cell carcinoma using the schedule previously
described by Atzpodien et al. (1990a). This is an outpatient
schedule, with low-dose IL-2 and INF-a administered sub-
cutaneously. This protocol resulted in a 29% response rate
with limited toxicity (Atzpodien et al., 1990a, 1991).
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Materials and methods
Patients
Patients had to have a histologically proven metastatic renal
cell carcinoma and evaluable disease to be eligible for this
study. Patients had an ECOG performance status of 0, 1 or 2
and an expected survival time exceeding 3 months. Prior
therapy (chemotherapy, immunotherapy, extensive radio-
therapy) had to be completed at least 4 weeks prior to the
protocol treatment. Excluded from the study were patients
receiving corticosteroids and patients with current evidence
of cardiovascular disease, pulmonary, hepatic or renal dys-
function, known seizure disorders or central nervous system
disease. Furthermore, patients with serious infections or
positivity for human immunodeficiency virus or hepatitis B
surface antigens were not eligible. Patients with central ner-
vous system metastases were also excluded, except if they had
been previously treated (surgery and/or radiotherapy) and
subsequently demonstrated stable disease or no evidence of
recurrence. In addition, adequate organ function was neces-
sary as defined by: white blood cell count of 3,500 mm-3 or
higher; platelet count of 120,000 mm-3 or higher; haemato-
crit above 30%; normal serum bilirubin level; creatinine level
less than 150ytmol 1'. Signed informed consent was obtained
from each patient before protocol treatment was begun.
Treatment
The treatment involved the subcutaneous administration of
IL-2 (EuroCetus, Amsterdam, The Netherlands) and INF-xo
(Shering Plough, Paris, France) in an outpatient setting. Each
course was completed in 7 weeks and could be repeated once
after 2 weeks of rest. In the first week, patients received a 2
day course of IL-2 at a dose of 9 x 106 IU m-2 every 12 h.
For the following 6 consecutive weeks, patients received IL-2
at a dose of 1.8 x 106 IU m-2 every 12 h for 5 days per week
and INF-a at a dose of 5 x 106 three times per week, as
shown in Figure 1. Two treatment courses were administered
except in case of progression of disease or drug-induced
toxicity. The first week of each course could be given in the
hospital wards and concomitant medications could be given
to reduce the side-effects of therapy. Most patients received
acetaminophen and/or indomethacin. No systematic
antibiotic prophylaxis was given.
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Figure 1 Scheme of treatment. (U), IL-2, 9 x 106 IU m-2; (V),
IL-2, 1.8 x 106 IUm-2; (*) IFN, 5 x 106. Each dot represents one
subcutaneous injection.
Response criteria
Complete response (CR) was defined as the complete disap-
pearance of all clinically detectable disease for at least 4
weeks. The duration of CR was calculated from the first date
of documentation of complete response to the date of first
observation of disease progression. A partial response (PR)
was defined as a 50% or greater decrease in the sum of the
products of the two longest perpendicular diameters of all
measurable lesions for at least 4 weeks without progression
of any assessable disease and without appearance of new
lesions. The duration of PR was calculated from the first date
of documentation of partial response to the date of first
observation of disease progression. Stable disease (SD) was
defined as a less than 25% increase or a less than 50%
decrease in tumour size without simultaneous progression of
any assessable lesion or appearance of any new lesions. Pro-
gressive disease (PD) was defined as an increase of more than
25% in measurable lesions or the appearance of new
lesions.
After each 7-week course of treatment patients were
evaluated for response. Patients presenting with CR, PR or
SD were further evaluated every 8 weeks for the first year
and every 3-4 months thereafter.
Survival duration was evaluated from the start of treat-
ment to date of last contact or to the date of death.
Results
Patient characteristics
From March 1990 to May 1991, 38 patients with metastatic
renal cell carcinoma were eligible for this study. All patients
were evaluated for tumour response and for toxicity. The
clinical characteristics of these patients are outlined in Table
I. Twenty-eight males and ten females took part in the study.
Median age was 58 (range 26-73). Thirty patients had an
ECOG performance status of 0 or 1 (79%), and eight had a
performance status of 2 (21.1%). The time from diagnosis of
renal cell carcinoma to occurrence of metastatic disease was
less than 24 months in 31 patients (81.6%), with a mean of
18.3 months. Thirty patients had a prior nephrectomy. Four
patients have been previously treated under immunotherapy
with IL-2 (one patient), with IL-2 and lymphokine-activated
killer (LAK) cells (two patients) and with IL-2, IFN and
LAK cells (one patient). In 11 patients (28.9%) the disease
was limited to one site only, while 15 (39.5%) and 12
(31.6%) presented metastatic disease at two or at least three
sites respectively. At the time of treatment, the metastatic
tumours were localised in the lung (27 patients), lymph nodes
(17 patients), bone, kidney and liver (ten patients) and brain
(three patients).
Administration of treatment
The 38 patients received a total of 56 courses of treatment
with 18 patients (47.3%) being treated with two courses. The
remaining patients were not eligible for further treatment
secondary to progression (15 patients), toxicity (three
patients) and surgery (one patient). Two patients received less
than 2 weeks of treatment because of rapid progression of
the disease. One patient asked to discontinue the treatment
Table I Characteristics of patients
Characteristics No. %
Eligible patients 38 100
Assessable patients
Response 38 100
Toxicity 38 100
Men/women 28/10 73.7/26.3
Age (years) median (range) 58 (26-73)
Performance status ECOG
0 15 39.5
1 15 39.5
2 8 21.1
Time from diagnosis
to first metastases
>24 months 7 18.4
<24 months 31 81.6
Site of metastatic disease
Lung 27 71.1
Lymph nodes 17 44.7
Bone 10 26.3
Kidney 10 26.3
Liver 10 26.3
Abdomen 3 7.9
Brain 3 7.9
Others 5 13.1
Prior therapy
None 5 13.2
Nephrectomy 30 78.9
Hormone therapy 3 7.9
Immunotherapy 4 10.5
Table II Toxicity of treatment
Number of patients with toxicities by
WHO grade
Adverse events I II III IV Total (%)
Chills 1 3 3 7 (18)
Fever 11 22 4 37 (97)
Fatigue/malaise 5 18 6 29 (76)
Anorexia 2 8 6 16 (42)
Skin disorders 2 6 3 11 (29)
Injection site reaction 38 38 (100)
Nausea/vomiting 5 9 5 19 (50)
Mucositis 1 1 (3)
Diarrhoea 1 6 7 (18)
Alkaline phosphatase 13 10 3 26 (68)
increased
SGOT increased 18 9 27 (71)
Bilirubinaemia 2 2 (5)
Oliguria 1 6 1 8 (21)
Hypercreatininaemia 13 2 15 (39)
Hypotension 8 2 10 (26)
Tachycardia 1 1 (3)
Weight increased 1 1 (3)
Dyspnoea 1 2 3 (8)
Agitation/anxiety 1 1 2 (5)
Confusion 4 1 5 (13)
Insomnia 2 2 (5)
Somnolence 1 1 (3)
Anemia 10 11 5 2 28 (74)
Leucopenia 4 2 1 7 (18)
Thrombocytopenia 1 1 (3)
after one single injection and was thereafter lost to follow-up.
Thirty-three patients (86.8%) received more than 80% of the
planned doses of IL-2 in their first course, while 15 (93.8%)
did so in the second course. Dose modifications of IL-2 were
required in 12 patients, representing a total of 20 events.
These changes were necessary because of worsening condi-
tion, patient refusal, confusion, fever or progression of
disease. Thirty-three patients (86.8%) received more than
80% of the planned doses of INF-o in the first course and 14
(87.5%) in the second course received more than 80% of theSUBCUTANEOUS IL-2 AND INF-a IN METASTATIC RENAL CANCER
Table III Characteristics of responding patients
Performance
status Prior Sites of Duration
Patient Age/sex (ECOG) nephrectomy metastasis Response (months)
I 55/M 0 Yes Lung CR 12
2 65/M 1 Yes Bone/liver PR 28+
Spleen/pleura
3 55/M 0 Yes Kidney PR 15
Lung/bone
4 63/M 0 Yes Lung PR 6
5 69/M 0 Yes Lung PR 6
6 59/M 0 Yes Lung PR 3
7 66/M 1 Yes Brain/lung/bone PR 1
planned dose of INF-o. The dose of INF-o had to be modi-
fied in nine patients because of worsening condition, fever or
progression of disease. Three patients were treated on an
inpatient basis because of the severe impairment of their
general condition with treatment. Treatment was stopped in
three patients after only one cycle, as a consequence of
toxicity in the absence of disease progression. Seventeen
patients had to delay the second cycle by 1-4 weeks in order
to regain their pretreatment performance status.
Toxicity oftreatment
Toxicities encountered were evaluated according to the WHO
grading system (Table II). The main toxicity consisted of an
alteration of general status, but most of the time this altera-
tion was mild or moderate with fever (97%), fatigue or
malaise (76%) or anorexia (42%). Digestive disorders were
commonly observed and usually consisted of nausea or
vomiting (50%), rather than diarrhoea (18%). Biological
hepatic disturbances of mild degree were frequent: increased
levels of serum glutamic-oxaloacetic transaminase (SGOT)
(71%) or ofalkaline phosphatase (68%). Bilirubin levels were
occasionally elevated (5%). Transient elevations of
creatininaemia were noted (grade 1, 34%; grade 2, 5%).
None of these biological side-effects altered the course of
treatment. Ten patients experienced moderate hypotension;
however, no other cardiac side-effects were noted. Ten
patients had neurological disturbances including repetitive
transient confusion events, mild insomnia and moderate
anxiety. These neurological manifestations were reversible at
the end of the treatment, but a feeling ofmild slower intellec-
tual capacities with some loss of memory could remain for
up to 2-3 weeks. Notably, all patients experienced transient
inflammation and local induration at the injection site.
One patient in this study was treated previously for brain
metastases with radiotherapy, and suffered subsequently from
a major infection for which he received antibiotics. This
therapy was given concomitantly with the cytokine treatment.
However, he rapidly developed a grade 4 leucopenia and a
grade 4 thrombocytopenia and died after 5 weeks of treat-
ment from progression of the disease.
Treatment response and survival
In 38 evaluable patients, one CR and six PRs were achieved.
Eleven patients had stable disease while 20 showed progres-
sion of their metastases. The objective response rate in
evaluable patients was 18.4% (95% confidence interval
6.1-30.7%). The characteristics of the responding patients
are presented in Table III. Sites of responses were lung, bone
and liver. The median duration of response was 6.7 months
(range 1-28.3 +). Median follow-up was 13 months (range
1-28.3). Median survival of all patients was 7.5 months.
Median survival of patients with objective responses was not
reached (range 11.1-28.3 +). Patients with SD and PD had a
median survival of 14.2 months (range 6.5-24.3) and 6.5
months (range 1.1 -20.0 +) respectively.
Discussion
The therapeutic effect of low-dose IL-2 and INF-a admini-
stered subcutaneously for the treatment of metastatic renal
cell carcinoma was recently reported by Atzpodien et al.
(1990a). This study showed a response rate of 29% with 2%
grade III side-effects. To extend these observations, we
studied a larger number of patients using the same treatment
schedule and dosage as outlined by Atzpodien et al.
In summary, our study does not precisely confirm the
results reported by Atzpodien et al. (1990a, 1991). It appears
that the treatment schedule is more toxic and less efficient for
the patients studied here. The toxicity encountered was
graded mainly mild to moderate, although we observed
10-15% grade III toxicity for fever, fatigue, malaise,
anorexia, nausea, vomiting and anaemia. These findings con-
trast with the relative infrequency of high toxicity reported
by Atzpodien et al. In addition, WHO grade III events such
as dyspnoea, agitation, confusion and oliguria were more
frequently observed in this study. The severity of toxicity was
responsible for three patients being hospitalised, for three
patients stopping treatment after one cycle and for 17
patients delaying the second cycle in order to recover their
pretreatment performance status. However, these differences
could be related to a different population of patients selected.
But although patients included in this study demonstrated an
obviously reduced general condition, there was no direct
correlation between the pretreatment performance status and
the severity of toxicity. The clinical presentation of toxicity
was similar to that seen in other trials in which IL-2 alone
was given subcutaneously (Atzpodien et al., 1990b;
Whitehead et al., 1990).
In this study, low-dose IL-2 combined with INF-a has
demonstrated clinical activity in patients with metastatic
renal cell carcinoma, with an objective response rate of 20%.
The observed difference from previously reported results
(Atzpodien et al., 1990a, 1991) could be explained by in-
clusion of patients with a poor predictive outcome (Elson et
al., 1988) and a poor predictive survival following IL-2 treat-
ment (Palmer et al., 1992). However, a difference between
responders and non-responders with regards to these prog-
nostic factors could not be found. Furthermore, non-re-
sponders did not receive significantly fewer IL-2 doses during
the first cycle than responders. Of the four patients previ-
ously treated with immunotherapy one had achieved partial
response and three stable disease until progression. With this
regimen, two achieved stable disease and in two disease
progressed. The three patients with pretreated brain meta-
stases at inclusion did not show progression in the brain,
even though they progressed in other sites.
A number of differences became apparent when these re-
sults were compared with those obtained with intravenous
regimens, in particular continuous infusion (Negrier et al.,
1989; Stein et al., 1991; Von der Maase et al., 1991; Escudier
et al., 1992). The severity of toxic events is dramatically
reduced with the subcutaneous regimen, with the lack of
clinical WHO grade IV toxicity. However, side-effects due to
IL-2 and INF-a are long-lasting and sufficiently incapacitat-
ing that further therapy was refused or delayed in some
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patients. The response rate appeared similar to that of
studies with i.v. regimens. However, the duration of response
seems to be shorter in this cohort, possibly in part because
some patients included in this study would not have been
considered to qualify for i.v. IL-2 therapy.
Our data suggest that subcutaneous IL-2 together with
IFN-a leads to similar efficacy as i.v. IL-2 alone (Palmer et
al., 1993), but a prospective randomised trial is necessary to
confirm this finding. In addition, the benefit of this combina-
tion of IL-2 and IFN-a compared with the use of alternative
schedules of subcutaneous IL-2 alone needs to be investi-
gated further (Stein et al., 1991; Sleijfer et al., 1992).
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